STAB Stock Overview
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Statera Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.026 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | -50.00% |
| 3 Month Change | -83.33% |
| 1 Year Change | -66.67% |
| 33 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| STAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.5% |
| 1Y | -66.7% | 15.6% | 30.7% |
Return vs Industry: STAB underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: STAB underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| STAB volatility | |
|---|---|
| STAB Average Weekly Movement | 117.4% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: STAB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: STAB's weekly volatility has decreased from 13262% to 117% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Mike Handley | www.staterabiopharma.com |
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis.
Statera Biopharma, Inc. Fundamentals Summary
| STAB fundamental statistics | |
|---|---|
| Market cap | US$7.26k |
| Earnings (TTM) | -US$91.83m |
| Revenue (TTM) | US$3.69m |
0.0x
P/S Ratio0.0x
P/E RatioIs STAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STAB income statement (TTM) | |
|---|---|
| Revenue | US$3.69m |
| Cost of Revenue | US$1.10m |
| Gross Profit | US$2.59m |
| Other Expenses | US$94.42m |
| Earnings | -US$91.83m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did STAB perform over the long term?
See historical performance and comparison